Metalloproteinase Inhibition Protects against Reductions in Circulating Adrenomedullin during Lead-induced Acute Hypertension

Basic and Clinical Pharmacology and Toxicology

Volumn 116, Issue 6, 2015, Pages 508-515

  Nascimento, Regina A ^a   Mendes, Gabryella ^a   Possomato Vieira, Jose S ^a   Gonçalves Rizzi, Victor Hugo ^a   Kushima, Hélio ^a   Delella, Flavia K ^a   Dias Junior, Carlos A ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENOMEDULLIN; CALCITONIN GENE RELATED PEPTIDE; DOXYCYCLINE; ENDOTHELIN 1; GELATIN; GELATINASE A; GELATINASE B; LEAD ACETATE; NITRIC OXIDE; ANTIOXIDANT; LEAD; MATRIX METALLOPROTEINASE INHIBITOR; NITRIC ACID DERIVATIVE; NITRITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HYPERTENSION; LEAD BLOOD LEVEL; LEAD POISONING; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SYSTOLIC BLOOD PRESSURE; WISTAR RAT; ZYMOGRAPHY; ANIMAL; BLOOD; BLOOD PRESSURE; CHEMICALLY INDUCED; DRUG EFFECTS; MALE; METABOLISM;

RATTUS; RATTUS NORVEGICUS;

ADRENOMEDULLIN; ANIMALS; ANTIOXIDANTS; BLOOD PRESSURE; CALCITONIN GENE-RELATED PEPTIDE; DOXYCYCLINE; ENDOTHELIN-1; HYPERTENSION; LEAD; LEAD POISONING; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; NITRATES; NITRITES; RATS; RATS, WISTAR;

EID: 84928716502     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12337     Document Type: Article

References (36)

1. Patrick L. Lead toxicity, a review of the literature. Part 1: exposure, evaluation, and treatment. Altern Med Rev 2006;11:2-22.
2. Healey N. Lead toxicity, vulnerable subpopulations and emergency preparedness. Radiat Prot Dosimetry 2009;134:143-51.
3. Awodele O, Popoola TD, Amadi KC, Coker HAB, Akintonwa A. Traditional medicinal plants in Nigeria-remedies or risks. J Ethnopharmacol 2013;150:614-8.
4. Renner R. Out of plumb: when water treatment causes lead contamination. Environ Health Perspect 2009;117:A542-7.
5. Glenn BS, Stewart WF, Links JM, Todd AC, Schwartz BS. The longitudinal association of lead with blood pressure. Epidemiology 2003;14:30-6.
6. Kosnett MJ, Wedeen RP, Rothenberg SJ, Hipkins KL, Materna BL, Schwartz BS et al. Recommendations for medical management of adult lead exposure. Environ Health Perspect 2007;15:463-71.
7. Rizzi E, Castro MM, Fernandes K, Barbosa F, Arisi GM, Garcia-Cairasco N et al. Evidence of early involvement of matrix metalloproteinase-2 in lead-induced hypertension. Arch Toxicol 2009;83:439-49.
8. Silveira EA, Siman FDM, de Oliveira Faria T, Vescovi MVA, Furieri LB, Lizardo JHF et al. Low-dose chronic lead exposure increases systolic arterial pressure and vascular reactivity of rat aortas. Free Radic Biol Med 2014;67:366-76.
9. Fiorim J, Ribeiro Júnior RF, Silveira EA, Padilha AS, Vescovi MVA, de Jesus HC et al. Low-level lead exposure increases systolic arterial pressure and endothelium-derived vasodilator factors in rat aortas. PLoS ONE 2011;6:e17117.
10. Simoes MR, Ribeiro Júnior RF, Vescovi MVA, de Jesus HC, Padilha AS, Stefanon I et al. Acute lead exposure increases arterial pressure: role of the renin-angiotensin system. PLoS ONE 2011;6:e18730.
11. Fioresi M, Furieri LB, Simoes MR, Ribeiro RF, Meira EF, Fernandes AA et al. Acute exposure to lead increases myocardial contractility independent of hypertension development. Braz J Med Biol Res 2013;46:178-85.
12. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003;92:827-39.
13. Barbosa F, Gerlach RF, Tanus-Santos JE. Matrix metalloproteinase-9 activity in plasma correlates with plasma and whole blood lead concentrations. Basic Clin Pharmacol Toxicol 2006;98:559-64.
14. Ding Y, Gonick HC, Vaziri ND, Liang K, Wei L. Lead-induced hypertension. III. Increased hydroxyl radical production. Am J Hypertens 2001;14:169-73.
15. Ali M, Schulz R. Activation of MMP-2 as a key event in oxidative stress injury to the heart. Front Biosci (Landmark Ed) 2009;14:699-716.
16. Martínez A, Oh H-R, Unsworth EJ, Bregonzio C, Saavedra JM, Stetler-Stevenson WG et al. Matrix metalloproteinase-2 cleavage of adrenomedullin produces a vasoconstrictor out of a vasodilator. Biochem J 2004;383:413-8.
17. Fernandez-Patron C, Stewart KG, Zhang Y, Koivunen E, Radomski MW, Davidge ST. Vascular matrix Metalloproteinase-2-Dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction. Circ Res 2000;87:670-6.
18. Fernandez-Patron C, Radomski MW, Davidge ST. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 1999;85:906-11.
19. Dursun N, Arifoglu C, Süer C, Keskinol L. Blood pressure relationship to nitric oxide, lipid peroxidation, renal function, and renal blood flow in rats exposed to low lead levels. Biol Trace Elem Res 2005;104:141-9.
20. Zhou Y, Zanao RA, Barbosa Jr F, Parsons PJ, Krugc FJ. Investigations of a W-Rh permanent modifier for the determination of Pb in blood by electrothermal atomic absorption spectrometry. Spectrochim Acta 2002;57:1291-300.
21. Moroz A, Delella FK, Lacorte LM, Deffune E, Felisbino SL. Fibronectin induces MMP2 expression in human prostate cancer cells. Biochem Biophys Res Commun 2013;430:1319-21.
22. Dias-Junior CA, Neto-Neves EM, Montenegro MF, Tanus-Santos JE. Hemodynamic effects of inducible nitric oxide synthase inhibition combined with sildenafil during acute pulmonary embolism. Nitric Oxide 2010;23:284-8.
23. Medina LO, Veloso CA, de Abreu Borges E, Isoni CA, Calsolari MR, Chaves MM et al. Determination of the antioxidant status of plasma from type 2 diabetic patients. Diabetes Res Clin Pract 2007;77:193-7.
24. Centers for Disease Control and Prevention (CDC). Blood lead levels-United States, 1999-2002. MMWR Morb Mortal Wkly Rep 2005;54:513-6.
25. He JZ, Quan A, Xu Y, Teoh H, Wang G, Fish JE et al. Induction of matrix metalloproteinase-2 enhances systemic arterial contraction after hypoxia. Am J Physiol Heart Circ Physiol 2007;292:H684-93.
26. Castro MM, Tanus-Santos JE. Inhibition of matrix metalloproteinases (MMPs) as a potential strategy to ameliorate hypertension-induced cardiovascular alterations. Curr Drug Targets 2013;14:335-43.
27. Nishikimi T, Kuwahara K, Nakagawa Y, Kangawa K, Nakao K. Adrenomedullin in cardiovascular disease: a useful biomarker, its pathological roles and therapeutic application. Curr Protein Pept Sci 2013;14:256-67.
28. Charvat J, Svab P, Havlin J, Bilek R, Zamrazil V. The significance of plasma adrenomedullin and calcitonin gene-related peptide concentration in patients with Type 2 diabetes mellitus who are treated for cardiovascular risk factors. Neuro Endocrinol Lett 2014;35:154-8.
29. Khalilmanesh F, Gonick HC, Weiler EWJ, Prins B, Weber MA, Purdy R et al. Effect of chelation treatment with dimercaptosuccinic acid (DMSA) on lead-related blood pressure changes. Environ Res 1994;65:86-99.
30. Khalil-Manesh F, Gonick H, Weiler E, Prins B, Weber M, Purdy R. Lead-induced hypertension: possible role of endothelial factors. Am J Hypertens 1993;6:723-9.
31. Caylak E, Halifeoglu I, Aydin S, Telo S, Bulmus O, Celik H. The effects of sulfur-containing compounds on total antioxidant capacity levels of liver, kidney and brain in lead-exposed rats. Turk Klinikleri J Med Sci 2007;27:823-8.
32. Caylak E, Halifeoglu I. Effects of sulfur-containing antioxidants on malondialdehyde and catalase levels of liver, kidney and brain in lead-exposed rats. Turk Klinikleri J Med Sci 2007;27:1-8.
33. Caylak E, Aytekin M, Halifeoglu I. Antioxidant effects of methionine, alpha-lipoic acid, N-acetylcysteine and homocysteine on lead-induced oxidative stress to erythrocytes in rats. Exp Toxicol Pathol 2008;60:289-94.
34. Caylak E, Halifeoglu I. The effects of lead on antioxidants enzymes in children and the therapeutic/prophylactic role of antioxidants. Cocuk Sagligi Hastaliklari Dergisi 2010;53:159-73.
35. Hamid SA, Totzeck M, Drexhage C, Thompson I, Fowkes RC, Rassaf T et al. Nitric oxide/cGMP signalling mediates the cardioprotective action of adrenomedullin in reperfused myocardium. Basic Res Cardiol 2010;105:257-66.
36. Castro MM, Rizzi E, Ceron CS, Guimaraes DA, Rodrigues GJ, Bendhack LM et al. Doxycycline ameliorates 2K-1C hypertension-induced vascular dysfunction in rats by attenuating oxidative stress and improving nitric oxide bioavailability. Nitric Oxide 2012;26:162-8.